Glucagon like Peptide 1 News and Research

RSS

Black Chokeberry (Aronia melanocarpa) diabetes benefits: Hope or hype?

Researchers compared the effects of fermented and non-fermented Aronia melanocarpa berries on glycemic markers in Type 2 Diabetes Mellitus patients. Despite the berries' high antioxidant potential and past studies suggesting benefits, this rigorous trial found no significant impact on waist circumference, insulin sensitivity, or glucose levels.

10 Oct 2023

Health experts redefine cardiovascular disease risk, prevention and management

Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association's flagship journal Circulation.

9 Oct 2023

How is TikTok's #Ozempic trend impacting diabetes patients?

A recent study analyzed TikTok videos with the hashtag "Ozempic," highlighting the platform's influence on promoting the weight loss drug. The surge in popularity resulted in medication shortages for diabetes patients, emphasizing the need for careful monitoring and collaboration among health professionals and social media platforms.

5 Oct 2023

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

5 Oct 2023

GLP-1 agonists linked to higher risk for gastrointestinal complications

They're being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems.

5 Oct 2023

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), a more aggressive form of the condition that normally responds less well to treatment, as it is at treating T2D diagnosed later in life, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has found.

4 Oct 2023

Experts to discuss if lasting remission from diabetes is feasible in real-world setting

At this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) experts will discuss if lasting remission from diabetes is feasible in the real-world setting.

4 Oct 2023

Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the Cyto-Mine® platform has been selected by FairJourney Biologics, a world leading end-to-end antibody partner, providing integrated services across antibody discovery, engineering, and production, to expand its cell line development capabilities.

From Fluidic Sciences and Sphere Bio 4 Oct 2023

How do different polyphenol-rich foods impact chronic diseases?

The potential of phytochemicals in promoting a healthy human diet to combat chronic disease.

27 Sep 2023

Understanding how exercise suppresses appetite could pave the way for new obesity drugs

The complex relationship between physical activity and energy balance – food intake versus energy expenditure – is still a challenge for science, especially in light of the rising worldwide prevalence of overweight and obesity

26 Sep 2023

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

25 Sep 2023

Could metformin be a game changer for heart health in non-diabetics?

Using Mendelian randomization, researchers found that altering seven metformin targets led to improved blood pressure and BMI in non-diabetic individuals. The study suggests the potential for metformin's role in reducing cardiovascular risks in the general population, although more research is needed.

24 Sep 2023

Cerba Healthcare to acquire Canadian contract research laboratory Cirion Biopharma Research to expand bioanalytical capabilities and shorten time-to-deploy complex clinical trials

Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC

From Cerba Research 11 Sep 2023

Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complications

The study used a genome-wide association study (GWAS) to analyze random glucose levels in nearly half a million non-diabetic subjects, uncovering 150 distinct genetic signals, including 53 new ones, linked to glycemic traits and type 2 diabetes. The research also discovered a causal effect of random glucose and type 2 diabetes on lung function, identifying lung dysfunction as a new diabetes complication.

10 Sep 2023

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Groundbreaking research published today in Nature Genetics describes the largest-ever study into the genetics of random "round-the-clock" blood glucose levels.

8 Sep 2023

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice. The findings suggest that this drug could be a promising treatment for obesity and offer a suitable animal model for future research.

3 Sep 2023

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction.

31 Aug 2023

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children's health.

28 Aug 2023

Semaglutide could be a game-changer for patients with HFpEF and obesity

Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

25 Aug 2023

New ESC Guidelines for the management of cardiovascular disease in patients with diabetes released

Patients with type 2 diabetes are more than twice as likely to develop cardiovascular disease (CVD) than their healthy peers.

25 Aug 2023

Glucagon like Peptide 1 News and Research

Black Chokeberry (Aronia melanocarpa) diabetes benefits: Hope or hype?

Health experts redefine cardiovascular disease risk, prevention and management

How is TikTok's #Ozempic trend impacting diabetes patients?

GLP-1 weight loss drugs linked to heightened GI risks, says new study

GLP-1 agonists linked to higher risk for gastrointestinal complications

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Experts to discuss if lasting remission from diabetes is feasible in real-world setting

Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows

How do different polyphenol-rich foods impact chronic diseases?

Understanding how exercise suppresses appetite could pave the way for new obesity drugs

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Could metformin be a game changer for heart health in non-diabetics?

Cerba Healthcare to acquire Canadian contract research laboratory Cirion Biopharma Research to expand bioanalytical capabilities and shorten time-to-deploy complex clinical trials

Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complications

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

Semaglutide could be a game-changer for patients with HFpEF and obesity

New ESC Guidelines for the management of cardiovascular disease in patients with diabetes released

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News